The transaction will not have any impact on J&J’s 2022 financial report. Following the acquisition, Abiomed’s stock stopped trading, according to a Dec. 22 J&J news release.
“The completion of this acquisition allows Johnson & Johnson MedTech to expand our portfolio in the high growth cardiovascular markets, adding solutions for heart recovery to our global market leading Biosense Webster electrophysiology business,” Ashley McEvoy, executive vice president and worldwide chair of medtech at J&J, said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.